Senseonics Stock Down Despite New FDA Approval for Eversense 365
BTIG Maintains Senseonics(SENS.US) With Hold Rating
BTIG analyst Marie Thibault maintains $Senseonics(SENS.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 34.7% and a total average return of -1.5% over the past
Sensenonics Shares Are Trading Higher After the Company Announced FDA Clearance for Its Next-generation Eversense 365 Continuous Glucose Monitoring (CGM) System for People With Type 1 and Type 2 Diabetes Aged 18 Years and Older.
FDA Clearance Announcement Sends Small Cap Soaring
Senseonics Announces First CGM
Express News | Senseonics Holdings Inc - Launch Expected Early in Q4 of 2024
Express News | Eversense 365 Receives FDA Clearance: The World’s First One Year Cgm
Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
HC Wainwright & Co. Reiterates Buy on Senseonics Holdings, Maintains $2 Price Target
Senseonics Holdings Analyst Ratings
Earnings Call: Senseonics Sees Growth With New CGM Systems on the Horizon
Analysts Conflicted on These Healthcare Names: Senseonics Holdings (SENS), PepGen Inc. (PEPG) and 4D Molecular Therapeutics (FDMT)
Earnings Call Summary | Senseonics(SENS.US) Q2 2024 Earnings Conference
Senseonics Holdings, Inc. (SENS) Q2 2024 Earnings Call Transcript
Senseonics: Q2 Earnings Snapshot
Express News | Senseonics Holdings Inc: Expect Full Year 2024 Global Net Revenue to Be in Range of $22 Mln to $24 Mln
Senseonics | 10-Q: Q2 2024 Earnings Report
Earnings Flash (SENS) SENSEONICS HOLDINGS Reports Q2 Revenue $4.9M, Vs. Street Est of $4.9M
Express News | Senseonics Holdings, Inc. Reports Second Quarter 2024 Financial Results
Express News | Senseonics Q2 Net Income USD -20.287 Million